Prosecution Insights
Prosecution Insights
31 pending office actions • 5 art units • 15 examiners • 0 of 31 (0%) have an AI response strategy ready • 32 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 30 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 30 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 2 (6%) |
| §103 only | 9 (29%) |
| §102 only | 1 (3%) |
| §112 only | 3 (10%) |
| No statute on record | 16 (52%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, CHRISTINA L | 5 | 46.8% | +51.2% |
| GIBBS, TERRA C | 4 | 64.1% | +10.6% |
| POLIAKOVA-GEORGAN, EKATERINA | 4 | 64.6% | +17.0% |
| HUDSON, AMY ROSE | 4 | 75.1% | +11.4% |
| SULLIVAN, STEPHANIE LAUREN | 2 | 60.9% | +38.7% |
| VYAS, KEYUR ANILKUMAR | 2 | 51.5% | +63.5% |
| VANHORN, ABIGAIL LOUISE | 2 | 46.7% | +22.1% |
| BRETZ, COREY LANE | 1 | 0.0% | +0.0% |
| CHONG, KIMBERLY | 1 | 72.4% | +12.7% |
| ANGELL, JON E | 1 | 70.7% | +21.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18247314 | SNCA IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING SNCA-ASSOCIATED NEURODEGENERATIVE DISEASES | GIBBS, TERRA C | 16d overdue |
| 18637183 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE | GIBBS, TERRA C | 9d overdue |
| 18259887 | 2'-MODIFIED NUCLEOSIDE BASED OLIGONUCLEOTIDE PRODRUGS | BRETZ, COREY LANE | 69d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18301089 | PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | CHONG, KIMBERLY | 127d overdue |
| 17945151 | COMPOSITIONS AND METHODS FOR TREATING SUBJECTS HAVING A HETEROZYGOUS ALANINE-GLYOXYLATE AMINOTRANSFERASE GENE (AGXT) VARIANT | HUDSON, AMY ROSE | 110d overdue |
| 17683423 | XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | HUDSON, AMY ROSE | 110d overdue |
| 17773508 | COMPOSITIONS AND METHODS FOR SILENCING DNAJB1-PRKACA FUSION GENE EXPRESSION | VYAS, KEYUR ANILKUMAR | 85d overdue |
| 18324191 | METHODS AND COMPOSITIONS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION | TRAN, CHRISTINA L | 52d overdue |
| 18382562 | METHODS OF TREATING TRANSTHYRETIN (TTR) MEDIATED AMYLOIDOSIS | POLIAKOVA-GEORGAN, EKATERINA | 51d overdue |
| 17736251 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | VANHORN, ABIGAIL LOUISE | 43d overdue |
| 18376217 | TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | HUDSON, AMY ROSE | 38d overdue |
| Art Unit | Apps |
|---|---|
| 1637 | 13 |
| 1635 | 9 |
| 1636 | 7 |
| 1691 | 1 |
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18978602 | SNCA-TARGETING SIRNA COMPOSITIONS FOR TREATING SNCA-ASSOCIATED DISEASE | SULLIVAN, STEPHANIE LAUREN | 1635 | Other | Non-Final OA | 33d | Pending | Dec 12, 2024 |
| 18637183 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE | GIBBS, TERRA C | 1635 | §101 | Non-Final OA | 9d overdue | Pending | Apr 16, 2024 |
| 18581511 | BETA-CATENIN (CTNNB1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | VYAS, KEYUR ANILKUMAR | 1637 | Other | Final Rejection | 79d | Pending | Feb 20, 2024 |
| 18427072 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | VANHORN, ABIGAIL LOUISE | 1636 | Other | Final Rejection | 5d overdue | Pending | Jan 30, 2024 |
| 18382562 | METHODS OF TREATING TRANSTHYRETIN (TTR) MEDIATED AMYLOIDOSIS | POLIAKOVA-GEORGAN, EKATERINA | 1637 | Other | Non-Final OA | 51d overdue | Pending | Oct 23, 2023 |
| 18376217 | TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | HUDSON, AMY ROSE | 1636 | Other | Final Rejection | 38d overdue | Pending | Oct 03, 2023 |
| 18259887 | 2'-MODIFIED NUCLEOSIDE BASED OLIGONUCLEOTIDE PRODRUGS | BRETZ, COREY LANE | 1635 | §103 | Non-Final OA | 69d | Pending | Jun 29, 2023 |
| 18324191 | METHODS AND COMPOSITIONS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION | TRAN, CHRISTINA L | 1637 | Other | Non-Final OA | 52d overdue | Pending | May 26, 2023 |
| 18302855 | METHODS AND COMPOSITIONS FOR TREATING PRIMARY HYPEROXALURIA | POLIAKOVA-GEORGAN, EKATERINA | 1637 | Other | Non-Final OA | 14d | Pending | Apr 19, 2023 |
| 18301089 | PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | CHONG, KIMBERLY | 1636 | Other | Non-Final OA | 127d overdue | Pending | Apr 14, 2023 |
| 18299220 | METHODS FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES USING TRANSTHYRETIN (TTR) iRNA COMPOSITIONS | GIBBS, TERRA C | 1635 | — | Non-Final OA | 28d | Pending | Apr 12, 2023 |
| 18247314 | SNCA IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING SNCA-ASSOCIATED NEURODEGENERATIVE DISEASES | GIBBS, TERRA C | 1635 | §101 | Non-Final OA | 16d overdue | Pending | Mar 30, 2023 |
| 18125167 | DIPEPTIDYL PEPTIDASE 4 (DPP4) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §103 | Non-Final OA | 25d overdue | Pending | Mar 23, 2023 |
| 17773508 | COMPOSITIONS AND METHODS FOR SILENCING DNAJB1-PRKACA FUSION GENE EXPRESSION | VYAS, KEYUR ANILKUMAR | 1637 | §103 | Non-Final OA | 85d overdue | Pending | Feb 09, 2023 |
| 18077271 | RNAi COMPOSITIONS AND METHODS OF USE THEREOF FOR DELIVERY BY INHALATION | GIBBS, TERRA C | 1635 | Other | Non-Final OA | 27d | Pending | Dec 08, 2022 |
| 17982819 | CHIRALLY-ENRICHED DOUBLE-STRANDED RNA AGENTS | ANGELL, JON E | 1637 | Other | Non-Final OA | 28d | Pending | Nov 08, 2022 |
| 17974596 | APOLIPOPROTEIN E (APOE) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | TRAN, CHRISTINA L | 1637 | §103 | Final Rejection | 4d overdue | Pending | Oct 27, 2022 |
| 17974598 | COMPLEMENT FACTOR B (CFB) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | TRAN, CHRISTINA L | 1637 | §112 | Final Rejection | 34d | Pending | Oct 27, 2022 |
| 17995568 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | MEYERING, SHABANA SHABBEER | 1635 | §103 | Final Rejection | — | Pending | Oct 05, 2022 |
| 17995035 | MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | SULLIVAN, STEPHANIE LAUREN | 1635 | Other | Non-Final OA | 32d overdue | Pending | Sep 29, 2022 |
| 17907664 | COMPOSITIONS AND METHODS FOR SILENCING DNAJC15 GENE EXPRESSION | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §103 | Non-Final OA | 15d overdue | Pending | Sep 28, 2022 |
| 17945151 | COMPOSITIONS AND METHODS FOR TREATING SUBJECTS HAVING A HETEROZYGOUS ALANINE-GLYOXYLATE AMINOTRANSFERASE GENE (AGXT) VARIANT | HUDSON, AMY ROSE | 1636 | §102 | Non-Final OA | 110d overdue | Pending | Sep 15, 2022 |
| 17802004 | G PROTEIN-COUPLED RECEPTOR 146 (GPR146) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | PERSONS, JENNA L | 1637 | §103 | Final Rejection | 30d | Pending | Aug 24, 2022 |
| 17794637 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | HUDSON, AMY ROSE | 1636 | §112 | Final Rejection | 2d overdue | Pending | Jul 22, 2022 |
| 17779706 | SYNTHESIS OF 3 -RNA OLIGONUCLEOTIDES | CREWS, JARET JAMES | 1691 | §103 | Non-Final OA | 26d overdue | Pending | May 25, 2022 |
| 17736251 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | VANHORN, ABIGAIL LOUISE | 1636 | Other | Non-Final OA | 43d overdue | Pending | May 04, 2022 |
| 17683423 | XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | HUDSON, AMY ROSE | 1636 | Other | Non-Final OA | 110d overdue | Pending | Mar 01, 2022 |
| 17672771 | NEUROFILAMENT LIGHT CHAIN (NFL) AS A BIOMARKER FOR TRANSTHYRETIN AMYLOIDOSIS POLYNEUROPATHY | TRAN, CHRISTINA L | 1637 | §112 | Final Rejection | 30d overdue | Pending | Feb 16, 2022 |
| 17611761 | ORAL DELIVERY OF OLIGONUCLEOTIDES | TRAN, CHRISTINA L | 1637 | Other | Final Rejection | 49d | Pending | Nov 16, 2021 |
| 17314909 | AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF | SHIN, DANA H | 1635 | — | Final Rejection | 13d | Pending | May 07, 2021 |
| 17250952 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BRANDSEN, BENJAMIN MICHAEL | 1693 | §103 | Final Rejection | 230d overdue | Pending | Apr 01, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial